tag:blogger.com,1999:blog-5574479.post2164294727791840102..comments2024-03-28T16:45:51.051+00:00Comments on The IPKat: Heartache for heartburn drugmaker, though court sweetens the bitter pillVerónica RodrÃguez Arguijohttp://www.blogger.com/profile/05763207846940036921noreply@blogger.comBlogger1125tag:blogger.com,1999:blog-5574479.post-20523802756814590302010-07-15T16:24:32.631+01:002010-07-15T16:24:32.631+01:00Check out paras 864 and 865 - in fact, the Court d...Check out paras 864 and 865 - in fact, the Court did not "reverse[] the Commission's finding that AstraZeneca breached EU rules by withdrawing market approvals for older versions of the medicine in Denmark and Norway, thus preventing market entry by generic producers and parallel importers". <br /><br />It upheld the Commission's finding that the deregistration was abusive by restricting generic access to the market in Denmark, Norway and Sweden. It also upheld the Commission's finding of abuse by restricting parallel imports into Sweden. <br /><br />However, it reversed the finding of abuse by restricting parallel imports into Denmark and Norway on the basis of lack of evidence that the deregistrations could have had such an effect in those countries.Anonymousnoreply@blogger.com